Cargando…

Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation

PURPOSE: Although patients with tuberculous destroyed lung (TDL) receive long-acting muscarinic antagonist (LAMA) inhaler therapy, its effectiveness is not clear. This study evaluated the effect of LAMA inhaler therapy on mortality in patients with TDL and airflow limitation. PATIENTS AND METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ho Cheol, Kim, Tae Hoon, Rhee, Chin Kook, Han, Minkyu, Oh, Yeon-Mok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407515/
https://www.ncbi.nlm.nih.gov/pubmed/30881003
http://dx.doi.org/10.2147/TCRM.S194324
_version_ 1783401570680963072
author Kim, Ho Cheol
Kim, Tae Hoon
Rhee, Chin Kook
Han, Minkyu
Oh, Yeon-Mok
author_facet Kim, Ho Cheol
Kim, Tae Hoon
Rhee, Chin Kook
Han, Minkyu
Oh, Yeon-Mok
author_sort Kim, Ho Cheol
collection PubMed
description PURPOSE: Although patients with tuberculous destroyed lung (TDL) receive long-acting muscarinic antagonist (LAMA) inhaler therapy, its effectiveness is not clear. This study evaluated the effect of LAMA inhaler therapy on mortality in patients with TDL and airflow limitation. PATIENTS AND METHODS: A retrospective cohort of 683 patients with TDL and airflow limitation was analyzed in this study. The mortality was compared between 177 patients treated with LAMA inhalers >360 days (LAMA group) and 506 patients not treated with LAMA inhalers or treated with LAMA inhalers for <360 days (non-LAMA group). Risk factors for mortality were analyzed with Cox proportional hazards models and survival analysis was performed after propensity score matching. RESULTS: Patients in the LAMA group appeared to have worse baseline characteristics, older mean age, lower lung function, higher X-ray severity, and were more likely to receive long-term oxygen therapy than those in the non-LAMA group. On multivariate analysis, LAMA inhaler usage was independently associated with lower risk of mortality (HR, 0.405; P=0.006) after adjusting age, gender, body mass index, smoking history, Charlson Comorbidity Index, lung function, X-ray severity, and long-term oxygen therapy. After propensity score matching to adjust for the above unbalanced baseline characteristics, patients in the LAMA group tended to have a better prognosis than those in the non-LAMA group (121 patients in each group, 5-year mortality rate: 2.5% vs 9.1%, P=0.057). If we performed the same analysis of propensity score matching even after excluding patients with corticosteroids/long-acting beta-2 agonist (ICS/LABA) usage, patients in the LAMA group had a better prognosis than those in the non-LAMA group (64 patients in each group, 5-year mortality rate: 3.1% vs 14.1%, P=0.039). CONCLUSION: LAMA inhaler treatment might reduce mortality in patients with TDL and airflow limitation.
format Online
Article
Text
id pubmed-6407515
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64075152019-03-16 Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation Kim, Ho Cheol Kim, Tae Hoon Rhee, Chin Kook Han, Minkyu Oh, Yeon-Mok Ther Clin Risk Manag Original Research PURPOSE: Although patients with tuberculous destroyed lung (TDL) receive long-acting muscarinic antagonist (LAMA) inhaler therapy, its effectiveness is not clear. This study evaluated the effect of LAMA inhaler therapy on mortality in patients with TDL and airflow limitation. PATIENTS AND METHODS: A retrospective cohort of 683 patients with TDL and airflow limitation was analyzed in this study. The mortality was compared between 177 patients treated with LAMA inhalers >360 days (LAMA group) and 506 patients not treated with LAMA inhalers or treated with LAMA inhalers for <360 days (non-LAMA group). Risk factors for mortality were analyzed with Cox proportional hazards models and survival analysis was performed after propensity score matching. RESULTS: Patients in the LAMA group appeared to have worse baseline characteristics, older mean age, lower lung function, higher X-ray severity, and were more likely to receive long-term oxygen therapy than those in the non-LAMA group. On multivariate analysis, LAMA inhaler usage was independently associated with lower risk of mortality (HR, 0.405; P=0.006) after adjusting age, gender, body mass index, smoking history, Charlson Comorbidity Index, lung function, X-ray severity, and long-term oxygen therapy. After propensity score matching to adjust for the above unbalanced baseline characteristics, patients in the LAMA group tended to have a better prognosis than those in the non-LAMA group (121 patients in each group, 5-year mortality rate: 2.5% vs 9.1%, P=0.057). If we performed the same analysis of propensity score matching even after excluding patients with corticosteroids/long-acting beta-2 agonist (ICS/LABA) usage, patients in the LAMA group had a better prognosis than those in the non-LAMA group (64 patients in each group, 5-year mortality rate: 3.1% vs 14.1%, P=0.039). CONCLUSION: LAMA inhaler treatment might reduce mortality in patients with TDL and airflow limitation. Dove Medical Press 2019-03-05 /pmc/articles/PMC6407515/ /pubmed/30881003 http://dx.doi.org/10.2147/TCRM.S194324 Text en © 2019 Kim et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kim, Ho Cheol
Kim, Tae Hoon
Rhee, Chin Kook
Han, Minkyu
Oh, Yeon-Mok
Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
title Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
title_full Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
title_fullStr Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
title_full_unstemmed Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
title_short Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
title_sort effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407515/
https://www.ncbi.nlm.nih.gov/pubmed/30881003
http://dx.doi.org/10.2147/TCRM.S194324
work_keys_str_mv AT kimhocheol effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation
AT kimtaehoon effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation
AT rheechinkook effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation
AT hanminkyu effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation
AT ohyeonmok effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation